重型β地中海贫血患者接受造血干细胞移植与传统治疗的长期生存比较
单中心病例对照研究纳入516例儿童及成人患者,258例接受同胞或不亲属造血干细胞移植,另随机选取258例年龄性别匹配的常规治疗患者。移植后30年总生存率与无地中海贫血生存率分别为82.6±2.7%和77.8±2.9%,常规治疗组总生存率为85.3±2.7%(P=NS)。
要点
- 移植后30年总生存率与常规治疗组无显著差异(82.6±2.7% vs 85.3±2.7%,P=NS)。
- 高危Pesaro评分(3级)与较低总生存(OR=1.99,95%CI 1.31-3.03)和无地中海贫血生存(OR=1.54,95%CI 1.12-2.12)相关。
- 曲奥舒凡方案与较低急性移植物抗宿主病风险相关(P=.004;OR=0.28,95%CI 0.12-0.67)。
核心结论
- 移植后脱离地中海贫血的患者30年生存率与常规治疗患者预期生存率相似,绝大多数移植存活者已治愈地中海贫血。
研究设计与样本
- 单中心病例对照研究,纳入516例儿童和成人患者,其中258例(中位年龄12岁,范围1-45岁)接受同胞(67%)或不亲属(33%)造血干细胞移植,97例为成人(年龄≥16岁)。
- 从常规治疗患者中随机选取258例年龄性别匹配的对照,接受输血支持和铁螯合治疗。
- 移植后中位随访11年(范围1-30年);预处理方案为白消安(80.6%)或曲奥舒凡为基础(19.4%)。
主要发现
- 移植患者30年总生存率和无地中海贫血生存率分别为82.6±2.7%和77.8±2.9%,常规治疗组总生存率为85.3±2.7%(P=NS)。
- II-IV级急性移植物抗宿主病和慢性移植物抗宿主病发生率分别为23.6%和12.9%;排斥反应概率为6.9%。
- 移植相关死亡率(13.8%)与常规治疗患者心血管事件死亡概率(12.2%)相似。
- 成人患者移植后23年总生存率和无地中海贫血生存率分别为70±5%和67.3±5%,常规治疗组总生存率为71.2±5%(P=NS)。
关键数值与推荐
- 高危Pesaro评分(3级)与较低总生存相关(OR=1.99,95%CI 1.31-3.03),与较低无地中海贫血生存相关(OR=1.54,95%CI 1.12-2.12)。
- 曲奥舒凡方案与较低急性移植物抗宿主病风险相关(P=.004;OR=0.28,95%CI 0.12-0.67)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation (HSCT) in thalassemia remains a challenge. We reported a single-centre case-control study of a large cohort of 516 children and adult patients treated with HSCT or blood transfusion support and iron chelation therapy; 258 patients (median age 12, range 1-45) underwent sibling (67%) or unrelated (33%) HSCT; 97 patients were adults (age ≥ 16 years). The median follow-up after HSCT was 11 years (range 1-30). The conditioning regimen was busulfan (80.6%) or treosulfan-based (19.4%). A cohort of 258 age-sex matched conventionally treated (CT) patients was randomly selected. In transplanted patients the 30-year overall survival (OS) and thalassemia-free survival (TFS) were 82.6 ± 2.7% and 77.8 ± 2.9%, compared to the OS of 85.3 ± 2.7% in CT patients (P = NS); The incidence of grade II-IV acute and chronic graft versus host disease (GvHD) was 23.6% and 12.9% respectively. The probability of rejection was 6.9%. Transplant-related mortality (TRM) (13.8%) was similar to the probability of dying of cardiovascular events in CT patients (12.2%). High-risk Pesaro score (class 3) was associated with lower OS (OR = 1.99, 95% C.I.=1.31-3.03) and TFS (OR = 1.54, 95% C.I.=1.12-2.12). In adult patients, the 23-years OS and TFS after HSCT were 70 ± 5% and 67.3 ± 5%, compared to 71.2 ± 5% of OS in CT (P = NS). Finally, treosulfan was associated with lower risk of acute GvHD (P = .004; OR = 0.28, 95% C.I.=0.12-0.67). In conclusion, the 30-year survival rate of ex-thalassemia patients after HSCT was similar to that expected in CT thalassemia patients, with the vast majority of HSCT survivors cured from thalassemia.
引用
- Caocci G, Orofino MG, Vacca A, et al. Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment. Am J Hematol. 2017. PMID: 28850704. doi:10.1002/ajh.24898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。